SAB Biotherapeutics (NASDAQ:SABS) Earns Buy Rating from HC Wainwright

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 200.30% from the stock’s previous close.

SABS has been the topic of a number of other research reports. Chardan Capital increased their target price on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Jefferies Financial Group began coverage on shares of SAB Biotherapeutics in a research report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price target for the company. Wall Street Zen cut SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Rodman & Renshaw restated a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics stock opened at $3.33 on Monday. The firm has a 50-day moving average of $3.70 and a 200-day moving average of $3.85. The stock has a market cap of $254.63 million, a PE ratio of -1.58 and a beta of 0.54. SAB Biotherapeutics has a 52-week low of $1.60 and a 52-week high of $6.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). As a group, sell-side analysts forecast that SAB Biotherapeutics will post -1.19 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SABS. PNC Financial Services Group Inc. acquired a new stake in shares of SAB Biotherapeutics during the 1st quarter worth approximately $29,000. State of Wyoming acquired a new position in SAB Biotherapeutics during the fourth quarter valued at approximately $34,000. ADAR1 Capital Management LLC lifted its stake in SAB Biotherapeutics by 75.6% during the fourth quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after purchasing an additional 11,344 shares during the last quarter. State Street Corp bought a new stake in SAB Biotherapeutics during the fourth quarter worth $49,000. Finally, Fifth Lane Capital LP acquired a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at $56,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.